Results 21 to 30 of about 105,036 (275)

Bridging the gap in patent assessment: The Index of Internal Effort framework for pharma innovations [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: The process of assessing patents is complex, and there is a gap in the literature on patent assessment at the time of filing. Aims: To assess patent complexity and the human effort involved in research, we test the effectiveness of the Index ...
Alisson A. de Oliveira, Celso B. dos Santos, Luiz A. Pilatti   +2 more
doaj   +1 more source

Implications of the pharmaceutical industry on the economies of developing countries [PDF]

مجلة الاجتهاد للدراسات القانونية والاقتصادية, 2021
The pharmaceutical industry is a strategic industry that is critical to health security and, to a greater extent, national security, enabling developed countries to take indirect control through pharmaceutical patents on developing countries, thanks to
مالكي محمد , قريقر فتيحة   +1 more
doaj   +1 more source

Drug patenting in India: looking back andlooking forward [PDF]

, 2015
It has now been 20 years since the TRIPS Agreement, which established minimum standards for intellectual property (IP) regulation, came into force. Its implementation in India has been controversial, and in particular Section 3(d), a provision designed ...
Sampat, Bhaven N., Shadlen, Kenneth C.
core   +1 more source

Pharmaceutical patents and the right to health – Portugal and Brazil (Vol.13, N.1)

Janus.net, 2022
The defence of the patent system's legitimacy, namely in the pharmaceutical field, is consolidated, although it is not exempt from criticism. Historically, when the patent law, a legal monopoly right, is confronted with the right of access to
Ruben Bahamonde Delgado
doaj   +1 more source

Letters to the MJM

McGill Journal of Medicine, 2020
In response to "TRIPS agreement and public health" by Junaid Subhan.
Bishnu Rath Giri, P. Ravi Shankar
doaj   +1 more source

Indian pharmaceutical patent prosecution: The changing role of Section 3(d). [PDF]

PLoS ONE, 2018
India, like many developing countries, only recently began to grant pharmaceutical product patents. Indian patent law includes a provision, Section 3(d), which tries to limit grant of "secondary" pharmaceutical patents, i.e.
Bhaven N Sampat, Kenneth C Shadlen
doaj   +1 more source

Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance [PDF]

, 2006
Lost in the cacophony surrounding the debate about high drug prices is the fundamental principle that pharmaceutical innovation will not occur without the prospect of outsized returns enabled through market exclusivity.
Chenine, Moustafa, Garcia Lozano, Marianela, Kabilan, Vandana   +2 more
core   +2 more sources

Can’t Buy Me Rights! The Contractual Structure of Asymmetrical Inter-firm Collaborations [PDF]

, 2006
The efficient allocation of control rights in inter-firm collaborations is a widely emphasized issue. In this paper, I empirically identify control rights and the allocation of these rights using a unique survey data set on collaborations between ...
Häussler, Carolin
core   +2 more sources

Pharmaceutical patents: General characteristics and current issues in the international context [PDF]

Pravni Zapisi, 2014
A patent can be defined as an exclusive right that is granted to the patent owner, which allows him to prevent others from making, selling, importing or using the invention, without license or authorization for a period of 20 years.
Lasić Ines
doaj  

Strategic Patenting of Pharmaceutical Inventions and the Public’s Right to Access Medicines: The South African Context

The African Journal of Information and Communication, 2015
Pharmaceutical firms’ use of strategic patenting to influence the markets within which their patented inventions sit is legally questionable. Such patenting entails filing patents with the intention of blocking potential competitors from innovating ...
Vuyisile Hobololo
doaj   +3 more sources